Business Wire

CA-CYARA

Share
Cyara Resolves Common Chatbot Failures with New Testing Capabilities

Cyara , provider of the award-winning Automated Customer Experience (CX) Assurance Platform, today unveiled innovative new chatbot testing features with the latest release of Cyara Botium , the industry’s leading one-stop solution for comprehensive, automated chatbot testing and assurance. The release comes just weeks after Cyara announced its acquisition of Botium to solidify its position as the global leader in CX testing and assurance.

Chatbots continue to experience tremendous growth driven by the meaningful benefits they deliver to businesses and customers alike, but they’re also commonly plagued with problems that include misinterpreted customer intent, delayed or disrupted hand-offs to live agents and security vulnerabilities. Negative chatbot experiences can have a devastating impact on a brand and result in customer churn.

The disconnect between what chatbots generally promise and what they deliver has created the need for solutions that can efficiently test and monitor the performance of chatbots and conversational AI without overburdening teams. With Cyara Botium’s holistic testing approach, brands can improve and continuously test the customer chatbot experience across all channels and platforms in all phases of the chatbot development lifecycle. Cyara Botium also addresses the rise in chatbot data breaches by improving general chatbot security, ensuring compliance with Open Web Application Security Project® (OWASP) security standards. The result: consistent, quality, secure experiences and, for new bots, shortened time to market.

Cyara Botium offers the following new features and capabilities:

AI-Powered Data & Test Generation

Cyara Botium’s new AI-Powered Data & Test Generation is built on the world’s largest natural language model. This enables organizations to quickly create relevant examples of intents and utterances in order to thoroughly train and test their chatbots. This cutting-edge feature dramatically improves the efficiency of chatbot teams, requiring mere minutes to generate new intent phrasing to the chatbot—an otherwise laborious, manual process that can take weeks to collect data from various sources. By using the largest pre-trained language model through Cyara Botium, customers can save AI-generated topics as new intents – thereby dramatically improving the chatbot’s ability to understand what the user is trying to achieve.

Extended Performance Testing

Cyara Botium has greatly enhanced the scalability of its performance testing by dramatically increasing the capacity of parallel test executions so that chatbot development teams can stress test by simulating very high volumes of interactions.

Interactive Voice Response (IVR) Channel and Voice Testing

The new release of Cyara Botium introduces two new test types. Users can now test bots in the IVR channel, ensuring they perform effectively as part of an IVR experience by generating calls that mimic real-time customer interactions. Users can also now conduct voice tests to ensure voicebots perform well in all environments, including mobile devices and browsers. Both of these new features ensure problems are unearthed well before they occur in production.

“It’s without question that chatbots are delivering benefits to businesses, but it’s imperative that organizations also realize that negative chatbot experiences can lead to chatbots hurting the business more than they help,” said Christoph Börner, Senior Director of Digital at Cyara. “Cyara Botium has already been a prominent market leader in testing conversational AI and is well ahead of the market needs. The innovative features introduced in this release reinforce our leadership, setting us even further ahead of any competition.”

Additional new features include multi-language General Data Protection Regulation (GDPR) testing for compliance with European Union (EU) security protocols, customizable reporting templates that appeal to any stakeholder and Single Sign-On (SSO) user authentication.

To learn more about Cyara Botium, please click here .

About Cyara’s Automated CX Assurance Platform

The award-winning Cyara Automated CX Assurance Platform enables companies to deliver better CX with less effort, cost, and risk. Cyara supports the entire CX software development lifecycle, from design to functional and regression testing, load testing, chatbot testing and production monitoring, ensuring enterprises can build flawless customer journeys across voice and digital channels.

About Cyara

Cyara is the world’s leading Automated Customer Experience (CX) Assurance platform, headquartered in Silicon Valley. Cyara’s cloud-based omnichannel assurance solutions for voice quality and chatbot testing accelerate the delivery of flawless customer journeys for enterprises while reducing the risk of customer-facing defects. Every day, major global brands trust the Cyara Platform to deliver customer smiles at scale. For more information, please visit cyara.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/Cyara

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye